Reuters logo
BRIEF-VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION
October 24, 2017 / 10:39 AM / 2 months ago

BRIEF-VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION

Oct 24 (Reuters) - Vical Inc:

* VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION

* ‍INITIAL STAGE OF PROGRAM WILL BE TO DEMONSTRATE PRECLINICAL PROOF OF CONCEPT FOR INHIBITING HBV INFECTION IN HUMAN LIVER MODEL IN H2 2018​

* ‍ANGES HAS PROVIDED PARTIAL FUNDING FOR INITIAL STAGE OF PROGRAM​

* ‍IF INITIAL STAGE OF PROGRAM IS SUCCESSFUL, VICAL EXPECTS THAT ANGES WILL CONTINUE TO PARTICIPATE IN FUNDING OF PROGRAM ​

* ‍ANGES GRANTED RIGHT OF FIRST REFUSAL TO NEGOTIATE WITH CO FOR EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE HEPATITIS B THERAPY IN JAPAN​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below